Modelling a population with Barrett's oesophagus from oesophageal adenocarcinoma incidence data

Scandinavian Journal of Gastroenterology

Volumn 42, Issue 3, 2007, Pages 308-317

  Van Blankenstein, Mark ^a,c   Looman, Caspar W N ^a   Kruijshaar, Michelle E ^a   Siersema, Peter D ^a   Kuipers, Ernst J ^a   Bytzer, Peter ^b  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b GLOSTRUP UNIVERSITY HOSPITAL   (Denmark)

^c NONE   (Netherlands)

Author keywords

Barrett's oesophagus; Cancer risk; EM algorithms; Epidemiology; Oesophageal adenocarcinoma

Indexed keywords

ADULT; AGED; ALGORITHM; ARTICLE; BARRETT ESOPHAGUS; BIRTH; CANCER INCIDENCE; CANCER MORTALITY; CAUSE OF DEATH; CONTROLLED STUDY; ESOPHAGEAL ADENOCARCINOMA; FEMALE; HUMAN; LIFE TABLE; MALE; MODEL; POPULATION RESEARCH; PREDICTION; PREVALENCE; PRIORITY JOURNAL;

ADENOCARCINOMA; AGE FACTORS; AGED; AGED, 80 AND OVER; ALGORITHMS; BARRETT ESOPHAGUS; DENMARK; ESOPHAGEAL NEOPLASMS; FEMALE; HUMANS; INCIDENCE; MALE; MIDDLE AGED; MODELS, STATISTICAL; PREDICTIVE VALUE OF TESTS; PREVALENCE; RESEARCH DESIGN; RISK FACTORS; SEX FACTORS;

EID: 33847188028     PISSN: 00365521     EISSN: 15027708     Source Type: Journal    
DOI: 10.1080/00365520600884130     Document Type: Article

References (68)

1. Naef AP, Savary M, Ozzello L. Columnar-lined lower esophagus: an acquired lesion with malignant predisposition. Report on 140 cases of Barrett's esophagus with 12 adenocarcinomas. J Thorac Cardiovasc Surg 1975;70:826-35.
2. Hamilton SR, Smith RR. The relationship between columnar epithelial dysplasia and invasive adenocarcinoma arising in Barrett's esophagus. Am J Clin Pathol 1987;87:301-12.
3. Hamilton SR, Smith RR, Cameron JL. Prevalence and characteristics of Barrett esophagus in patients with adenocarcinoma of the esophagus or esophagogastric junction. Hum Pathol 1988;19:942-8.
4. Haggitt RC. Barrett's esophagus, dysplasia, and adenocarcinoma. Hum Pathol 1994;25:982-93.
5. Cameron AJ, Lomboy CT, Pera M, Carpenter HA. Adenocarcinoma of the esophagogastric junction and Barrett's esophagus. Gastroenterology 1995;109:1541-6.
6. Devesa SS, Blot WJ, Fraumeni JF, Jr. Changing patterns in the incidence of esophageal and gastric carcinoma in the United States. Cancer 1998;83:2049-53.
7. Bytzer P, Christensen PB, Damkier P, Vinding K, Seersholm N. Adenocarcinoma of the esophagus and Barrett's esophagus: a population-based study. Am J Gastroenterol 1999;94:86-91.
8. Botterweck AA, Schouten LJ, Volovics A, Dorant E, van Den Brandt PA. Trends in incidence of adenocarcinoma of the oesophagus and gastric cardia in ten European countries. Int J Epidemiol 2000;29:645-54.
9. Bollschweiler E, Wolfgarten E, Gutschow C, Holscher AH. Demographic variations in the rising incidence of esophageal adenocarcinoma in white males. Cancer 2001;92:549-55.
10. El-Serag HB. The epidemic of esophageal adenocarcinoma. Gastroenterol Clin North Am 2002;31:421-40, viii.
11. El-Serag HB, Mason AC, Petersen N, Key CR. Epidemiological differences between adenocarcinoma of the oesophagus and adenocarcinoma of the gastric cardia in the USA. Gut 2002;50:368-72.
12. van Blankenstein M, Hop WCJ, Looman CWN, Bytzer P. The incidence of adenocarcinoma and squamous cell carcinoma of the esophagus; Barrett's esophagus makes a difference. Am J Gastroenterol 2005;100:766-74.
13. Shaheen NJ, Crosby MA, Bozymski EM, Sandler RS. Is there publication bias in the reporting of cancer risk in Barrett's esophagus? Gastroenterology 2000;119:333-8.
14. Spechler SJ, Lee E, Ahnen D, Goyal RK, Hirano I, Ramirez F, et al. Long-term outcome of medical and surgical therapies for gastroesophageal reflux disease: follow-up of a randomized controlled trial. JAMA 2001;285:2331-8.
15. van Blankenstein M, Looman CWN, Johnston BJ, Caygill CPJ. Age and sex distribution of the prevalence of Barrett's esophagus found in a primary referral endoscopy center. Am J Gastroenterol 2005;100:568-76.
16. van Soest EM, Siersema PD, Dieleman JP, Sturkenboom JMC, Kuipers EJ. Age and sex distribution of the incidence of Barrett's esophagus found in a Dutch primary care population. Am J Gastroenterol 2005;100:2599-600.
17. Eaden JA, Abrams KR, Mayberry JF. The risk of colorectal cancer in ulcerative colitis: a meta-analysis. Gut 2001;48:526-35.
18. Cameron AJ, Zinsmeister AR, Ballard DJ, Carney JA. Prevalence of columnar-lined (Barrett's) esophagus. Comparison of population-based clinical and autopsy findings. Gastroenterology 1990;99:918-22.
19. Ronkainen J, Aro P, Storskrubb T, Johansson SE, Lind T, Bolling-Sternevald E, et al. Prevalence of Barrett's esophagus in the general population: an endoscopic study. Gastroenterology 2005;129:1825-31.
20. van Blankenstein M, Hop WCJ, Looman CWN, Bytzer P. The incidence of adenocarcinoma and squamous cell carcinoma of the esophagus; Barrett's esophagus makes a difference. Am J Gastroenterol 2005;100:766-74.
21. Dempster AP, Laird NM, Rubin DB. Maximal likelihood from incomplete data via the EM algorithm. J R Statist Soc B 1977;39:1-38.
22. Anonymous, Danish Statistical Yearbook 1992. Copenhagen: 1992.
23. GOSPE. Barrett's esophagus: epidemiological and clinical results of a multicentric survey. Gruppo Operativo per lo Studio delle Precancerosi dell'Esofago (GOSPE). Int J Cancer 1991;48:364-8.
24. Cameron AJ, Lomboy CT. Barrett's esophagus: age, prevalence, and extent of columnar epithelium. Gastroenterology 1992;103:1241-5.
25. Brown LM, Silverman DT, Pottern LM, Schoenberg JB, Greenberg RS, Swanson GM, et al. Adenocarcinoma of the esophagus and esophagogastric junction in white men in the United States: alcohol, tobacco, and socioeconomic factors. Cancer Causes Control 1994;5:333-40.
26. Nordling CO. A new theory on the cancer-inducing mechanism. Br J Cancer 1953;7:68-72.
27. Armitage P, Doll R. The age distribution of cancer and multistage theory of carcinogenesis. Br J Cancer 1954;8:1-12.
28. Heidenreich WF, Luebeck EG, Hazelton WD, Paretzke HG, Moolgavkar SH. Multistage models and the incidence of cancer in the cohort of atomic bomb survivors. Radiat Res 2002;158:607-14.
29. Dulai GS. Surveying the case for surveillance. Gastroenterology 2002;122:820-3.
30. Cameron AJ, Ott BJ, Payne WS. The incidence of adenocarcinoma in columnar-lined (Barrett's) esophagus. N Engl J Med 1985;313:857-9.
31. van der Burgh A, Dees J, Hop WC, van Blankenstein M. Oesophageal cancer is an uncommon cause of death in patients with Barrett's oesophagus. Gut 1996;39:5-8.
32. Conio M, Cameron AJ, Romero Y, Branch CD, Schleck CD, et al. Secular trends in the epidemiology and outcome of Barrett's oesophagus in Olmsted County, Minnesota. Gut 2001;48:304-9.
33. Eckardt VF, Kanzler G, Bernhard G. Life expectancy and cancer risk in patients with Barrett's esophagus: a prospective controlled investigation. Am J Med 2001;111:33-7.
34. Anderson LA, Murray LJ, Murphy SJ, Fitzpatrick DA, Johnston BT, Watson RG, et al. Mortality in Barrett's oesophagus: results from a population based study. Gut 2003;52:1081-4.
35. van Soest EM, Dieleman JP, Siersema PD, Sturkenboom MC, Kuipers EJ. Increasing incidence of Barrett's oesophagus in the general population. Gut 2005;54:1062-6.
36. Provenzale D, Kemp JA, Arora S, Wong JB. A guide for surveillance of patients with Barrett's esophagus. Am J Gastroenterol 1994;89:670-80.
37. Provenzale D, Schmitt C, Wong JB. Barrett's esophagus: a new look at surveillance based on emerging estimates of cancer risk. Am J Gastroenterol 1999;94:2043-53.
38. Gudlaugsdottir S, van Blankenstein M, Dees J, Wilson JH. A majority of patients with Barrett's oesophagus are unlikely to benefit from endoscopic cancer surveillance. Eur J Gastroenterol Hepatol 2001;13:639-45.
39. Spechler SJ, Barr H. Review article: screening and surveillance of Barrett's oesophagus: what is a cost-effective framework? Aliment Pharmacol Ther 2004;19(Suppl 1):49-53.
40. Johansson S, Wallander MA, Ruigomez A, Garcia Rodriguez LA. Is there any association between myocardial infarction, gastro-oesophageal reflux disease and acid-suppressing drugs? Aliment Pharmacol Ther 2003;18:973-8.
41. Solaymani-Dodoran M, Logan RFA, West J, Card T. Mortality associated with Barrett's esophagus and gastroesophageal reflux disease diagnoses: a population based cohort study. Am J Gastroenterol 2005;100:2616-21.
42. Loffeld RJ, Werdmuller BF, Kuster JG, Perez-Perez GI, Blaser MJ, Kuipers EJ, et al. Colonization with cagA-positive Helicobacter pylori strains inversely associated with reflux esophagitis and Barrett's esophagus. Digestion 2000;62:95-9.
43. Sharma P. Helicobacter pylori: a debated factor in gastroesophageal reflux disease. Dig Dis 2001;19:127-33.
44. Sharma VK, Crowell CWH. Infection with H. pylori or cag A+/ H. pylori is protective against Barrett's esophagus (BE) and esophageal adenocarcinoma (EAC): A meta-analysis. Gastroenterology 2004;126:A-87.
45. Ye W, Held M, Lagergren J, Engstrand L, Blot WJ, McLaughlin JK, et al. Helicobacter pylori infection and gastric atrophy: risk of adenocarcinoma and squamous-cell carcinoma of the esophagus and adenocarcinoma of the gastric cardia. J Natl Cancer Inst 2004;96:388-96.
46. Dworak O, Kuspert G. Re: Adenocarcinoma of the esophagus: role of obesity and diet. J Natl Cancer Inst 1995;87:847-8.
47. Chow WH, Blot WJ, Vaughan TL, Risch HA, Gammon MD, Stanford JL, et al. Body mass index and risk of adenocarcinomas of the esophagus and gastric cardia. J Natl Cancer Inst 1998;90:150-5.
48. Lagergren J, Bergstrom R, Nyren O. Association between body mass and adenocarcinoma of the esophagus and gastric cardia. Ann Intern Med 1999;130:883-90.
49. Caygill CP, Johnston DA, Lopez M, Johnston BJ, Watson A, Reed PI, et al. Lifestyle factors and Barrett's esophagus. Am J Gastroenterol 2002;97:1328-31.
50. Hampel H, Abraham NS, El-Serag HB. Meta-analysis: obesity and the risk for gastroesophageal reflux disease and its complications. Ann Intern Med 2005;143:199-211.
51. El-Serag HB, Kvapil P, Hacken-Bitar J, Kramer JR. Abdominal obesity and the risk of Barrett's esophagus. Am J Gastroenterol 2005;100:2151-6.
52. Spechler SJ. Carcinogenesis at the gastroesophageal junction: free radicals at the frontier. Gastroenterology 2002;122:1518-20.
53. Fletcher J, Wirz A, Young J, Vallance R, McColl KE. Unbuffered highly acidic gastric juice exists at the gastroesophageal junction after a meal. Gastroenterology 2001;121:775-83.
54. Iijima K, Henry E, Moriya A, Wirz A, Kelman AW, McColl KE, et al. Dietary nitrate generates potentially mutagenic concentrations of nitric oxide at the gastroesophageal junction. Gastroenterology 2002;122:1248-57.
55. McColl KE. When saliva meets acid: chemical warfare at the oesophagogastric junction. Gut 2005;54:1-3.
56. Wilson KT, Fu S, Ramanujam KS, Meltzer SJ. Increased expression of inducible nitric oxide synthase and cyclooxygenase-2 in Barrett's esophagus and associated adenocarcinomas. Cancer Res 1998;58:2929-34.
57. Asanuma K, Iijima K, Sugata H, Ohara S, Shimosegawa T, Yoshimura T, et al. Diffusion of cytotoxic concentrations of nitric oxide generated luminally at the gastro-oesophageal junction of rats. Gut 2005;54:1072-7.
58. Hameeteman W, Tytgat GN, Houthoff HJ, van den Tweel JG. Barrett's esophagus: development of dysplasia and adenocarcinoma. Gastroenterology 1989;96:1249-56.
59. Schnell TG, Sontag SJ, Chejfec G, Aranha G, Metz A, O'Connell S, et al. Long-term nonsurgical management of Barrett's esophagus with high-grade dysplasia. Gastroenterology 2001;120:1607-19.
60. Van der Veen AH, Dees J, Blankensteijn JD, Van Blankenstein M. Adenocarcinoma in Barrett's oesophagus: an overrated risk. Gut 1989;30:14-8.
61. Hage M, Siersema PD, van Dekken H, Steyerberg EW, Dees J, Kuipers J. Oesophageal cancer incidence and mortality in patients with long-segment Barrett's oesophagus after a mean follow-up of 12.7 years. Scand J Gastroenterol 2004;39:1175-9.
62. Chang JT, Katzka DA. Gastroesophageal reflux disease, Barrett esophagus, and esophageal adenocarcinoma. Arch Intern Med 2004;164:1482-8.
63. Lagergren J, Bergstrom R, Lindgren A, Nyren O. Symptomatic gastroesophageal reflux as a risk factor for esophageal adenocarcinoma. N Engl J Med 1999;340:825-31.
64. Sabel MS, Pastore K, Toon H, Smith JL. Adenocarcinoma of the esophagus with and without Barrett mucosa. Arch Surg 2000;135:831-5; discussion 836.
65. Azzopardi JG, Menzies T. Primary oesophageal adenocarcinoma. Confirmation of its existence by the finding of mucous gland tumours. Br J Surg 1962;49:497-506.
66. Raphael HA, Ellis FH Jr, Dockerty MB. Primary adenocarcinoma of the esophagus. Ann Surg 1966;164:785.
67. Fabre A, Tansey DK, Dave U, Wright M, Teare JP, Rosin DR, et al. Adenocarcinoma in situ arising from the submucosal oesophageal mucous glands. Eur J Gastroenterol Hepatol 2003;15:1047-9.
68. Aitkin M, Anderson D, Francis B, Hinde J. Statistical Modeling in GLIM. Oxford: Clarendon Press; 1989.